Blood Reviews
Volume 22 , Pages S35-S41 , December 2008

Long-term efficacy and safety of deferasirox

  • Maria Domenica Cappellini

      Affiliations

    • Corresponding Author InformationUniversità di Milano, Fondazione Ospedale Maggiore Policlinico, Mangiagalli, Regina Elena IRCCS, Milan 20122, Italy Tel.: +39 02 503 20288; fax: +39 02 503 20296

References 

  1. Hider RC , Zhou T . The design of orally active iron chelators . Ann NY Acad Sci . 2005;1054:141–154
  2. Olivieri NF , Brittenham GM . Iron-chelating therapy and the treatment of thalassaemia . Blood . 1997;89:736–761
  3. Deferoxamine (Desferal®) package insert. Novartis 2002.
  4. Kushner JP , Porter JP , Olivieri NF . Secondary iron overload . Hematology Am Soc Hematol Educ Program . 2001;47–61
  5. Deferiprone (Ferriprox®) package insert. Apotex Europe Ltd. 1999.
  6. Cappellini MD , Cohen A , Piga A , et al.   A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassaemia . Blood . 2006;107:3455–3462
  7. Deferasirox (Exjade®) package insert. Novartis 2005.
  8. Thalassaemia International Federation  . In: Iron overload. Guidelines for the Clinical Management of Thalassaemia . 2nd Ed.. Cyprus: Nicosia; 2007;p. 31–63
  9. Wonke B , Wright C , Hoffbrand AV . Combined therapy with deferiprone and desferrioxamine . Br J Haematol . 1998;106:252–253
  10. Piga A , Roggero S , Vincinguerra T , et al.   Deferiprone: new insight . Ann NY Acad Sci . 2005;1054:169–174
  11. Peng CT , Wu KH , Wu SF , et al.   Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan . Hemoglobin . 2006;30(1):125–130
  12. Kolnagou A , Kontoghiorghes GJ . Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassaemia. The Protocol of the International Committee on Oral Chelators . Hemoglobin . 2006;30:239–249
  13. Daar S , Pathare AV . Combined therapy with desferrioxamine and deferiprone in beta thalassaemia major patients with transfusional iron overload . Ann Hematol . 2006;85:315–319
  14. Mourad FH , Hoffbrand AV , Sheikh-Taha M , et al.   Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients . Br J Haematol . 2003;121:187–189
  15. Gomber S , Saxena R , Madan N . Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children . Indian J Pediatr . 2004;41:21–27
  16. Galanello R , Kattamis A , Piga A , et al.   A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassaemia . Haematologica . 2006;91:1241–1243
  17. Aydinok Y , Ulger Z , Nart D , et al.   A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassaemia major . Haematologica . 2007;92:1599–1606
  18. Tanner MA , Galanello R , Dessi C , et al.   A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance . Circulation . 2007;115:1876–1884
  19. Tanner MA , Galanello R , Dessi C , et al.   Combined chelation therapy in thalassaemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction . J Cardiovasc Magn Reson . 2008;25:12
  20. Piga A , Galanello R , Forni GL , et al.   Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassaemia patients with transfusional iron overload . Haematologica . 2006;91:873–880
  21. Galanello R , Piga A , Forni GL , et al.   Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in paediatric patients with beta-thalassaemia major . Haematologica . 2006;91:1343–1351
  22. Cohen AR , Glimm E , Porter JB . Effect of transfusional iron intake on response to chelation therapy in beta-thalassaemia major . Blood . 2008;111:583–587
  23. Cappellini MD , Bejaoui M , Agaoglu L , et al.   Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassaemia . Clin Ther . 2007;29:909–917
  24. Vichinsky E , Onyekwere O , Porter J , et al.   A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease . Br J Haematol . 2007;136:501–508
  25. Vichinsky E , Pakbaz Z , Onyekwere O , et al.   Patient-reported outcomes of deferasirox (Exjade(R), ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial . Acta Haematol . 2008;119:133–141
  26. Porter J , Galanello R , Saglio G , et al.   Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study . Eur J Haematol . 2008;80:168–176
  27. List AF , Baer MR , Steensma D , et al.   Deferasirox (ICL670; Exjade®) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS) . Blood . 2007;110: abstract 1470.
  28. Cappellini MD , Vichinsky E , Ford JM , et al.   Evaluation of deferasirox (Exjade®, ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) (less than or equal to) 1000 ng/mL in long-term studies . Blood . 2007;110: abstract 3795.
  29. Cappellini MD , Vichinsky E , Galanello R , et al.   Long-term treatment with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, is effective in patients with transfusion-dependent anaemias . Blood . 2007;110: abstract 2777.
  30. Porter JB , Cohen AR , Ford JM , et al.   Impact of dose adjustments on serum ferritin (SF) levels during long-term treatment with once-daily, oral deferasirox (Exjade®, ICL670) . Blood . 2007;110: abstract 2778.
  31. Piga A , Vichinsky E , Forni GL , et al.   Long-term efficacy and safety with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, in paediatric patients . Blood . 2007;110: abstract 2774.
  32. Vichinsky E , Coates TD , Thompson AA , et al.   Long-term efficacy and safety of deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, in patients with sickle cell disease (SCD) . Blood . 2007;110: abstract 3395.
  33. Gabutti V , Piga A . Results of long-term iron-chelating therapy . Acta Haematol . 1996;95:26–36
  34. Olivieri NF , Nathan DG , MacMillan JH , et al.   Survival in medically treated patients with homozygous beta-thalassaemia . N Engl J Med . 1994;331:574–578
  35. Telfer PT , Prestcott E , Holden S , et al.   Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major . Br J Haematol . 2000;110:971–977
  36. Borgna-Pignatti C , Rugolotto S , De Stefano P , et al.   Survival and complications in patients with thalassaemia major treated with transfusion and deferoxamine . Haematologica . 2004;89:1187–1193

PII: S0268-960X(08)70007-9

doi: 10.1016/S0268-960X(08)70007-9

Blood Reviews
Volume 22 , Pages S35-S41 , December 2008

Article Tools